Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Platelet microRNAs and vascular injury
Elena V. Dolmatova, Kathy K. Griendling
Elena V. Dolmatova, Kathy K. Griendling
Published February 18, 2019
Citation Information: J Clin Invest. 2019;129(3):962-964. https://doi.org/10.1172/JCI127580.
View: Text | PDF
Commentary

Platelet microRNAs and vascular injury

  • Text
  • PDF
Abstract

Vascular smooth muscle cell (VSMC) phenotype switching from a contractile state to a synthetic phenotype has been implicated in intimal remodeling during vascular injury. While multiple studies have focused on dedifferentiation of VSMCs, prevention of VSMC-mediated excessive repair remains poorly understood. In this issue of the JCI, Zeng et al. identified a mechanism by which platelet-derived microRNA-223 (miRNA-223) reverses VSMC dedifferentiation. The authors show that suppression of proliferation occurs after platelet internalization by VSMCs. Moreover, they demonstrate that miRNA-223 inhibits dedifferentiation and intimal hyperplasia in diabetic mice by decreasing PDGFRβ expression in VSMCs. Together, these results identify platelet-derived miRNA-223 as a potential therapeutic target in vascular injury.

Authors

Elena V. Dolmatova, Kathy K. Griendling

×

Figure 1

Summary of the possible mechanisms for platelet-derived miRNA transfer during vascular injury.

Options: View larger image (or click on image) Download as PowerPoint
Summary of the possible mechanisms for platelet-derived miRNA transfer d...
With intact endothelium, platelets are quiescent. When the endothelial barrier is compromised, platelets are activated, form a clot, and release various factors promoting vessel repair. They also release microparticles (MPs) containing miRNAs that are taken up by endothelial cells (and possibly other cells) and exhibit various effects on protein expression in recipient cells. Next, the platelets are taken up by VSMCs and lysed, releasing miRNAs into cytoplasm of VSMCs. In particular, miRNA-223, -143, and -145 released in VSMC cytoplasm decrease expression of PDGFRβ, KLF5, and KLF4, thereby suppressing VSMC dedifferentiation and excessive repair.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts